New Intestinal-Type Ampullary Carcinoma Cell Line DPC-X3 Established
Author Information
Author(s): Chai Changpeng, Miao Xin, Su Yuanhui, Yu Cheng, Tang Huan, Li Lu, Wang Zhengfeng, Yi Jianfeng, Ye Zhenzhen, Miao Long, Zhang Hui, Hu Zhao, Chen Luyang, Wu Keren, Li Ning, Wang Linpei
Primary Institution: Lanzhou University Second Hospital
Hypothesis
The establishment of a new cell line will enhance the understanding of intestinal-type ampullary carcinoma.
Conclusion
The DPC-X3 cell line provides a valuable model for studying intestinal-type ampullary carcinoma and drug resistance.
Supporting Evidence
- DPC-X3 cells exhibited stable passaging for over 60 generations.
- The cell line showed a doubling time of 79 hours.
- DPC-X3 cells formed tumors when inoculated into mice.
- Drug susceptibility tests indicated resistance to multiple chemotherapy agents.
- Immunohistochemical analysis confirmed the cell line's characteristics consistent with intestinal-type ampullary carcinoma.
Takeaway
Researchers created a new cell line from a patient with ampullary cancer to help study the disease and test new treatments.
Methodology
The cell line was established from tumor tissue, cultured, and characterized through various assays including drug susceptibility tests.
Limitations
The study lacks comparison with existing intestinal-type ampullary carcinoma cell lines.
Participant Demographics
72-year-old Asian male with no prior tobacco use or significant medical history.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website